thromboprophylaxis

Recently, I referenced two clinical trials published in the NEJM which compared a new oral anticoagulant,rivaroxaban, with the low molecular weight heparin enoxaparin for thromboprophylaxis in patients undergoing hip arthroplasty and knee replacement surgery.

Archive 2008-06-01 james gaulte 2008

Recently, I referenced two clinical trials published in the NEJM which compared a new oral anticoagulant,rivaroxaban, with the low molecular weight heparin enoxaparin for thromboprophylaxis in patients undergoing hip arthroplasty and knee replacement surgery.

More on rivaroxaban trials james gaulte 2008

This refers to the situation in which a patient receiving heparin thromboprophylaxis develops symptomatic VTE.

Should we consider HIT (heparin induced thrombocytopenia) in cases of DVT and PE? james gaulte 2007

This refers to the situation in which a patient receiving heparin thromboprophylaxis develops symptomatic VTE.

Archive 2007-01-01 james gaulte 2007

Oral apixaban was more effective than subcutaneous enoxaparin for thromboprophylaxis after knee replacement, an international phase III trial found.

MedPageToday.com - medical news plus CME for physicians 2010

Of an estimated 25 000 deaths in England each year attributable to hospital acquired venous thromboemobolism (VTE), many are potentially preventable. 1 2 Despite the substantial evidence base for the benefits of thromboprophylaxis this was used in only about half of eligible patients and many healthcare professionals seemed to be unaware of the risks. 3 4

Latest headlines from BMJ 2010

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Clinical Cases and Images: CasesBlog 2010

Of an estimated 25 000 deaths in England each year attributable to hospital acquired venous thromboemobolism (VTE), many are potentially preventable. 1 2 Despite the substantial evidence base for the benefits of thromboprophylaxis this was used in only about half of eligible patients and many healthcare professionals seemed to be unaware of the risks. 3 4

Latest headlines from BMJ Hill, J., Treasure, T., On behalf of the National 2010

"A pragmatic initial approach to reduction of the rates of morbidity and mortality resulting from venous thromboembolism in ambulatory patients with inflammatory bowel disease would be non-pharmacological thromboprophylaxis, including patients 'education and awareness of risk and signs and symptoms of venous thromboembolism, and use of support stockings."

innovations-report 2010

"A pragmatic initial approach to reduction of the rates of morbidity and mortality resulting from venous thromboembolism in ambulatory patients with inflammatory bowel disease would be non-pharmacological thromboprophylaxis, including patients 'education and awareness of risk and signs and symptoms of venous thromboembolism, and use of support stockings."

PhysOrg.com - latest science and technology news stories PhysOrg Team 2010